Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

HISTORICAL FACTS: Creative medical shares soar on positive data from stemspine pilot study - Caught on Camera

  • Creative Medical Technology Holdings (NASDAQ:CELZ) has announced positive two-year follow-up data from its StemSpine pilot study.
  • The data showed significant efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects reported.
  • StemSpine is a patented procedure that utilizes a patient's bone marrow aspirate to treat chronic lower back pain.
  • There were no safety-related concerns for up to two years, and the StemSpine procedure resulted in an efficacy rate of 87% in the treated patients. 
  • The Company plans to submit a manuscript for publication in a peer-reviewed journal and present the data at future orthopedic/sports medicine conferences. 
  • Price Action: CELZ shares are up 80.30% at $3.07 on the last check Wednesday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.